Cardiology Today's Intervention Current Issue

The following articles appeared in the print edition of Cardiology Today's Intervention.

Table of Contents

• First, Do No Harm
• A Conversation with Howard C. Herrmann, MD
• Abbott to Separate Into Two Companies
• Maryland Cardiologist Given Sentence for Unnecessary Stenting
• Unnecessary Procedures on Cutting Block for CMS Reimbursement
• ACC, STS Launch US TAVR Registry
• Consequences of 30-Day Readmission After PCI Found Dire at 1 Year
• CPORT-E: On-Site Cardiac Surgery Capability Did Not Influence Elective Angioplasty Results
• Genetic, Drug-Related Factors May Play Role in Early Stent Thrombosis
• ISAR-REACT 4: Outcomes Similar for Bivalirudin vs. Abciximab-Heparin Combo
• Long-Term Outcomes Encouraging for High-Risk Patients Undergoing TAVR
• Outcomes Comparable for PCI vs. CABG in Left Main CAD
• Phase 3 Trial Underway to Test Ranolazine in Patients After PCI
• Randomized Trial to Compare BVS with EES in Patients with CAD
• Suboptimal Transfer Times Reported for Most Patients Needing PCI
• Updated PCI Guidelines: ‘Most Evidence-Based to Date’
• Use of Stress Imaging After Revascularization Highly Dependent on Billing Method
• The Why and How of CTO Interventions
• PCI Optimization Through Combined FFR, OCT Platform
• Weighing Revascularization Options in Multivessel Disease
• DES: A Promising Future Strategy for ED
• Cangrelor: A Novel Treatment for Bridging Antiplatelet Therapy in Patients Undergoing Surgery
• Balloon-Expandable Stent Gains FDA Approval for Use in Narrowed Iliac Arteries
• Embolic Protection Device Lands CE Mark
• FDA Approves Transcatheter Valve for Patients with Inoperable AS
• FDA Panel Gives Unanimous Nod to First DES for PAD
• The Take Home: TCT